Ifinatamab Deruxtecan vs. Docetaxel for Metastatic Castration-Resistant Prostate Cancer

A Phase 3, Open-label study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (Ideate-Prostate01)

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3, Open-label study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (Ideate-Prostate01)

For More Information:

https://clinicaltrials.gov/study/NCT06925737?term=Ideate-Prostate01&rank=1